Symetrique helps healthcare companies estimate market opportunity using a stronger evidence base than traditional sample-driven research. We combine real-world data, epidemiology, prevalence and incidence sources, public claims and utilization data, registries, standards-of-care research, and disease-state context to estimate the size and structure of the market across countries, regions, segments, and treatment populations.
A better market estimate starts with a better window into the market and a stronger contextual understanding of how that market functions.
Use prevalence, incidence, and disease burden data to estimate the size of the underlying patient population across regions and geographies.
Distinguish between total disease burden, diagnosed population, treated patients, eligible patients, and untreated opportunity.
Segment the market by line of therapy, site of care, payer mix, provider specialty, geography, care setting, or channel.
Use treatment guidelines, publications, protocols, and targeted primary research to interpret how patients move through diagnosis and treatment.
Combine the quantitative market model with disease-state context, regional care patterns, local policy differences, and expert interpretation so the estimate reflects how the market actually behaves.
Support pipeline prioritization, pre-launch planning, and existing-product reassessment with more grounded estimates of addressable opportunity.
Estimate market opportunity for early-stage assets to support portfolio prioritization and R&D investment decisions.
Build comprehensive market models to support launch planning, commercial strategy, and sales forecasting.
Update market models with current data to understand market evolution and growth opportunities post-launch.
Size the market opportunity for diagnostic products by understanding disease prevalence and testing patterns.
Estimate medical device market size and adoption potential across care settings and regions.
Map disease market opportunity across geographies to support regional strategies and expansion planning.